arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Vanda Pharmaceuticals Inc.

VNDA
$5.03 ▼ -0.19 (-3.64%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

Vanda Pharmaceuticals Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $296.4M
Dividend Yield —
Revenue Growth 8.7% ↗
Op. Margin -70.0% ↘
ROIC -73.5% ↘
FCF / Share $-1.87 ↘
Trailing P/E —
Price / Book 0.9x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$216.10M
↑ +8.7% —
Net Income Profit after all expenses
$-220.47M
↓ -1066.5% —
Operating Margin Operating profit as % of sales
-70.0%
↓ -242.0% 4th
FCF / Share Free cash flow per share
$-1.87
↓ -570.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
4
Returns
13
Cash Quality ↓
40

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 68 quarters